Loading...
Market
Story
FDA Approves Eli Lilly's Zepbound (tirzepatide) as First and Only Treatment for Obstructive Sleep Apnea in Adults with Obesity
Dec 20, 2024, 09:34 PM
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's Zepbound® (tirzepatide) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. This approval marks Zepbound as the first and only prescription medication specifically indicated for this condition in this patient population. The approval was confirmed by multiple sources, highlighting its significance in addressing sleep apnea associated with obesity.
View original story
Similar markets
Less than 20 • 25%
20 to 40 • 25%
40 to 60 • 25%
More than 60 • 25%
European Union • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%
Approved in US only • 33%
Approved in US and one other major market • 33%
Approved in US and multiple other major markets • 33%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Less than 1 million • 25%
1 million to 2 million • 25%
2 million to 3 million • 25%
More than 3 million • 25%
Less than 100,000 • 25%
100,000 to 200,000 • 25%
200,000 to 300,000 • 25%
More than 300,000 • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Less than 5 • 25%
5 to 10 • 25%
11 to 20 • 25%
More than 20 • 25%
European Medicines Agency (EMA) • 25%
Medicines and Healthcare products Regulatory Agency (MHRA) • 25%
Therapeutic Goods Administration (TGA) • 25%
Other • 25%
Less than 5 countries • 25%
5 to 10 countries • 25%
11 to 20 countries • 25%
More than 20 countries • 25%